NP regimen as adjuvant chemotherapy for breast cancer: final result of a phase II trialOxidative stressCoronary artery diseaseEndothelium derived relaxation factorNitric oxideL-ArginineIncreased oxidative stress has been linked with impaired endothelial function in atherosclerosis and may play a vital role ...
Chemotherapy medicinesare used to kill cancer cells. You may receive one medicine or a combination of medicines. Inhibitor medicinesmay be given to help destroy the cancer cells. One medicine helps your immune system kill the cells. Another medicine makes the cells die by preventing them from bei...
Figure 5. Time to recurrence, breast cancer mortality, and overall mortality for chemotherapy versus no adjuvant chemotherapy Left: four or more cycles of any anthracycline (Anth)-based regimen—eg, standard 4AC. Right: standard or near-standard CMF. RR (and its 95% CI)=event rate ratio, fr...
Recently two Phase III clinical trials have demonstrated that chemotherapy in combination with checkpoint inhibitors significantly increased pCR rate and prolonged progression-free survival in patients with triple negative breast cancers20,37. However, there was still limited understanding about the molecular ...
The FDA has approved pembrolizumab for postoperative adjunctive therapy in TNBC patients or further chemotherapy in patients with locally recurrent, unresectable, or mTNBC with high PD-L1 expression [203]. The IMpassion031 trial displayed that combining atezolizumab with a standard chemotherapy regimen mea...
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and chemotherapy still serves as the cornerstone treatment functioning by inducing cytotoxic cell death. Notably, emerging evidence suggests that dying cell-released signals may induce cancer progression and metastasis ...
Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance to therapy and therefore understanding the underlying mechanisms is an urgent challenge. Chemotherapy, routinely used to treat breast cancer, induces extensive
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the su
TNBC, triple-negative breast cancer; BC, breast cancer; BCT, conservative surgery; CHT, chemotherapy; DFS, disease-free survival; LR, local relapse; DR, distant relapse; RT, radiotherapy; OS, overall survival; CMF, cyclophosphamide–methotrexate–5-fluorouracil; BLBC, basal-like breast cancer; PF...
Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance to therapy and therefore understanding the underlying mechanisms is an urgent challenge. Chemotherapy, routinely used to treat breast cancer, induces extensive